Jin Sheng, Teng Xu, Xiao Lin, Xue Hongmei, Guo Qi, Duan Xiaocui, Chen Yuhong, Wu Yuming
1 Department of Physiology, Hebei Medical University, Hebei 050017, China.
2 Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Hebei 050017, China.
Exp Biol Med (Maywood). 2017 Dec;242(18):1831-1841. doi: 10.1177/1535370217732325. Epub 2017 Oct 3.
Reductions in hydrogen sulfide (HS) production have been implicated in the pathogenesis of hypertension; however, no studies have examined the functional role of hydrogen sulfide in hypertensive heart disease. We hypothesized that the endogenous production of hydrogen sulfide would be reduced and exogenous hydrogen sulfide would ameliorate cardiac dysfunction in N-nitro- L-arginine methyl ester ( L-NAME)-induced hypertensive rats. Therefore, this study investigated the cardioprotective effects of hydrogen sulfide on L-NAME-induced hypertensive heart disease and explored potential mechanisms. The rats were randomly divided into five groups: Control, Control + sodium hydrosulfide (NaHS), L-NAME, L-NAME + NaHS, and L-NAME + NaHS + glibenclamide (Gli) groups. Systolic blood pressure was monitored each week. In Langendorff-isolated rat heart, cardiac function represented by ±LV dP/dt and left ventricular developing pressure was recorded after five weeks of treatment. Hematoxylin and Eosin and Masson's trichrome staining and myocardium ultrastructure under transmission electron microscopy were used to evaluate cardiac remodeling. The plasma nitric oxide and hydrogen sulfide concentrations, as well as nitric oxide synthases and cystathionine-γ-lyase activity in left ventricle tissue were determined. The protein expression of p-Akt, Akt, p-eNOS, and eNOS in left ventricle tissue was analyzed using Western blot. After five weeks of L-NAME treatment, there was a time-dependent hypertension, cardiac remodeling, and dysfunction accompanied by a decrease in eNOS phosphorylation, nitric oxide synthase activity, and nitric oxide concentration. Meanwhile, cystathionine-γ-lyase activity and hydrogen sulfide concentration were also decreased. NaHS treatment significantly increased plasma hydrogen sulfide concentration and subsequently promoted the Akt/eNOS/NO pathway which inhibited the development of hypertension and attenuated cardiac remodeling and dysfunction. The cardioprotective effects of NaHS were counteracted by Gli which inhibited the Akt/eNOS/NO pathway. This suggests that the effects of hydrogen sulfide were mediated by the activation of the K channels. In conclusion, hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease via the activation of the Akt/eNOS/NO pathway, which was mediated by K channels. Impact statement 1. We found that HS ameliorated L-NAME-induced cardiac remodeling and dysfunction, and played a protective role in L-NAME-induced hypertensive heart disease, which the existing studies have not reported. 2. HS activated the Akt/eNOS/NO pathway, thereby playing a cardioprotective role in L-NAME-induced hypertensive heart disease. 3. The cardioprotective effect of HS was mediated by ATP-sensitive potassium channels.
硫化氢(HS)生成减少与高血压的发病机制有关;然而,尚无研究探讨硫化氢在高血压性心脏病中的功能作用。我们推测,在N-硝基-L-精氨酸甲酯(L-NAME)诱导的高血压大鼠中,内源性硫化氢生成会减少,外源性硫化氢会改善心脏功能障碍。因此,本研究调查了硫化氢对L-NAME诱导的高血压性心脏病的心脏保护作用,并探索了潜在机制。将大鼠随机分为五组:对照组、对照组+硫氢化钠(NaHS)、L-NAME组、L-NAME+NaHS组和L-NAME+NaHS+格列本脲(Gli)组。每周监测收缩压。在Langendorff离体大鼠心脏中,治疗五周后记录以±左心室dp/dt和左心室舒张末压表示的心脏功能。采用苏木精-伊红染色、Masson三色染色以及透射电子显微镜下的心肌超微结构来评估心脏重塑。测定血浆一氧化氮和硫化氢浓度,以及左心室组织中一氧化氮合酶和胱硫醚-γ-裂解酶活性。使用蛋白质印迹法分析左心室组织中p-Akt、Akt、p-eNOS和eNOS的蛋白表达。L-NAME治疗五周后,出现了时间依赖性的高血压、心脏重塑和功能障碍,同时伴有eNOS磷酸化、一氧化氮合酶活性和一氧化氮浓度降低。与此同时,胱硫醚-γ-裂解酶活性和硫化氢浓度也降低。NaHS治疗显著提高了血浆硫化氢浓度,随后促进了Akt/eNOS/NO途径,从而抑制了高血压的发展,减轻了心脏重塑和功能障碍。Gli抑制了Akt/eNOS/NO途径,抵消了NaHS的心脏保护作用。这表明硫化氢的作用是由钾通道的激活介导的。总之,硫化氢通过激活Akt/eNOS/NO途径改善了L-NAME诱导的高血压性心脏病,该途径由钾通道介导。影响声明1. 我们发现硫化氢改善了L-NAME诱导的心脏重塑和功能障碍,并在L-NAME诱导